<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01484262</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-3962</org_study_id>
    <secondary_id>U1111-1123-5044</secondary_id>
    <nct_id>NCT01484262</nct_id>
  </id_info>
  <brief_title>Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2</brief_title>
  <official_title>Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The intention of this health service research study is to
      obtain data from daily routine to evaluate the quality of life and the costs of the disease
      for patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life)</measure>
    <time_frame>At the end of the observational period (52 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cost of patient's diseases</measure>
    <time_frame>At the end of the observational period (52 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of patient education</measure>
    <time_frame>At the end of the observational period (52 weeks)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1344</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Any insulin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.</description>
    <arm_group_label>Liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin</intervention_name>
    <description>Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.</description>
    <arm_group_label>Any insulin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with type 2 diabetes mellitus, currently treated with oral antidiabetics
        (OADs), who need treatment intensification with insulin or liraglutide due to inadequate
        blood glucose control.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any study-related activities. (Study-related
             activities are any procedures related to recording of data according to the protocol)

          -  Patients willing and able to give signed consent on matching patient data with sick
             fund data

          -  Patients diagnosed with type 2 diabetes mellitus, currently treated with oral
             antidiabetic medication, who need treatment intensification with insulin or
             liraglutide (VictozaÂ®) due to inadequate blood glucose control

          -  Patient is a member of the involved sick fund (AOK Plus)

        Exclusion Criteria:

          -  Known or suspected contra-indication to the relevant study product according to
             current SPC

          -  Previous participation in this study

          -  History of type 1 diabetes mellitus

          -  Previous insulin treatment excluding emergency administration (treatment duration up
             to a maximum of 3 days)

          -  Previous treatment with liraglutide

          -  History of diabetic gastroparesis, diabetic precoma or diabetic ketoacidosis

          -  Progressive fatal disease

          -  Any reason in judgement of the treating physician that precludes study participation
             e.g. lack of compliance, safety concerns, alcohol or drug abuse

          -  Patients without legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

